Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in bringing ...
The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Evercore ISI Group on September 11, 2025. The analyst firm set a price target for $475.00 expecting VRTX to rise to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback